E2086
/ Eisai
- LARVOL DELTA
Home
Next
Prev
1 to 12
Of
12
Go to page
1
September 03, 2025
E2086, a Selective Orexin Receptor-2 Agonist, Study for Promoting Wakefulness in Patients With Narcolepsy Type-1
(WSS 2025)
- "Materials and E2086-A001-101 was a multicenter, randomized, double-blind, double-dummy, single-dose, 5-period crossover study evaluating the efficacy, safety, and tolerability of three dose strengths of E2086 compared with placebo (PBO) and modafinil in adult subjects with NT1. These data demonstrate that E2086 has the potential to improve daytime wakefulness in patients with NT1. The efficacy/safety profile supports continued investigation of E2086 in the narcolepsy patient population."
Clinical • Cataplexy • Narcolepsy • Sleep Disorder
May 12, 2025
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=22 | Completed | Sponsor: Eisai Inc. | Active, not recruiting ➔ Completed | N=40 ➔ 22
Enrollment change • Trial completion • Narcolepsy • Sleep Disorder
February 26, 2025
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Eisai Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Narcolepsy • Sleep Disorder
January 16, 2025
A Study of E2086 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=32 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed
Trial completion
August 27, 2024
A Study of E2086 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=32 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
August 20, 2024
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Narcolepsy • Sleep Disorder
July 01, 2024
A Study of E2086 in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=32 | Not yet recruiting | Sponsor: Eisai Inc.
New P1 trial
June 17, 2024
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Eisai Inc.
New P1 trial • Narcolepsy • Sleep Disorder
April 19, 2024
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
(clinicaltrials.gov)
- P1 | N=53 | Completed | Sponsor: Eisai Inc. | Recruiting ➔ Completed
Trial completion
August 28, 2023
E2086, a novel selective Orexin-2 receptor agonist
(WSS 2023)
- No abstract available
March 10, 2023
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Eisai Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
February 27, 2023
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Eisai Inc.
New P1 trial
1 to 12
Of
12
Go to page
1